Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations
Open Access
- 9 March 2010
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 65 (upplement ), ii5-ii10
- https://doi.org/10.1093/jac/dkq015
Abstract
Influenza is a transmissible viral pathogen that continues to cause substantial morbidity and mortality. Oseltamivir is an orally administered antiviral medication that selectively inhibits the influenza neuraminidase enzymes that are essential for viral replication. Treatment of infected children ≥1 year and adults of all ages may decrease the severity and duration of the symptoms of infection, while prophylactic dosing can prevent their onset. Oseltamivir is ingested in the form of a prodrug (oseltamivir phosphate) that is rapidly converted by hepatic esterases into the active metabolite, oseltamivir carboxylate. Oseltamivir carboxylate has high bioavailability and penetrates sites of infection at concentrations that are sufficient to inhibit viral replication. The pharmacokinetics of oseltamivir and oseltamivir carboxylate are dose proportional after repeated doses of up to 500 mg twice daily. This predictable profile means that oseltamivir is suitable for use in diverse patient populations, which may include young children and elderly patients, various ethnic groups and those with renal or hepatic impairment. As the potential for drug interactions is low, oseltamivir is also suitable for use in patients with co-morbid conditions who are likely to be receiving concomitant medications.This publication has 22 references indexed in Scilit:
- The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysisNephrology Dialysis Transplantation, 2006
- Probenecid with Oseltamivir for Human Influenza A (H5N1) Virus Infection?The New England Journal of Medicine, 2006
- Wartime tactic doubles power of scarce bird-flu drugNature, 2005
- Neuraminidase Inhibitors for InfluenzaThe New England Journal of Medicine, 2005
- Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylateBritish Journal of Clinical Pharmacology, 2005
- Oseltamivir distributes to influenza virus replication sites in the middle ear and sinuses.Clinical Drug Investigation, 2004
- Lack of pharmacokinetic interaction between the oral anti‐influenza neuraminidase inhibitor prodrug oseltamivir and antacidsBritish Journal of Clinical Pharmacology, 2002
- The Anti-Influenza Drug Oseltamivir Exhibits Low Potential to Induce Pharmacokinetic Drug Interactions via Renal Secretion—Correlation of in Vivo and in Vitro StudiesDrug Metabolism and Disposition, 2002
- Comparison of the Anti-Influenza Virus Activity of RWJ-270201 with Those of Oseltamivir and ZanamivirAntimicrobial Agents and Chemotherapy, 2001
- Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104Antimicrobial Agents and Chemotherapy, 1997